FluroPharma Medical, Inc. (FPMI) Reports Positive Phase I Safety Results for CardioPET
FluoroPharma Inc., a company developing breakthrough cardiovascular molecular imaging agents for the Positron Emission Tomography (PET) market, announced positive Phase I safety results for CardioPET, the company’s lead product. The trial was designed to evaluate safety, distribution and dosimetry of CardioPET as a PET tracer for myocardial imaging in healthy subjects and patients with Coronary Artery Disease (CAD). Dr. David Elmaleh, Chairman and scientific founder of FluoroPharma, presented findings from the Phase I trial at the “Clinical Trials Update” session at a Society of Nuclear Medicine conference in Denver, CO. CardioPET is a novel metabolic cardiac PET imaging agent that…